Scientifically, it's a cyclic heptapeptide with high affinity for MC4R (EC50 ~1 nM), making it highly specific for central arousal pathways.[4] It boosts desire, arousal, and lubrication through neurological activation, offering benefits like increased motivation and physical readinessdistinct from vascular drugs like sildenafil.[1][4][5] Studies show it improves HSDD symptoms, with 51% of women reporting significant desire boosts in phase 3 trials.[1] Biohacker Ben Greenfield has noted: "PT-141 enhances response efficiently, making it a go-to for biohacking intimacy without side effects of traditional meds."[17] For experts, its brain-targeted action avoids cardiovascular risks, positioning it as a versatile tool for HSDD, with preclinical data showing sustained dopamine release
This means the agency determined it cannot be used by licensed compounding pharmacies for compounded medications under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
Possible side effects include: Nausea, diarrhea, vomiting, constipation, mild to moderate abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia, flatulence, gastroenteritis, loss of lean muscle mass and gastroesophageal reflux disease
IL-18, interleukin 18
they are experimental compounds, frequently labeled for research use only. The FDA and other regulators have taken specific actions against compounding certain peptides (including BPC-157) as bulk substances because of insufficient safety data and potential for harm
